6 Aptamers for Targeted Therapy
157
Table 6.3
AS1411-based therapeutic agent targeted delivery platform
Targeting platform
Therapeutic agents
Target cell line
In vitro/In vivo Ref.
Aptamer–drug hybrid
Dox
Huh7
Y/Y
[39]
Aptamer–drug hybrid
Melittin
A549
Y/N
[200]
Chitosan
miR-145
MCF-7
Y/N
[201]
poly(ethyleneglycol)-poly(β-amino esters) polymeric micelles
Dox
MCF-7
Y/N
[134]
Micelle(chitosan-ss-polyethylenimine-urocanic acid)
TLR4-siRNA and Dox
A549
Y/Y
[202]
PLGA-lecithin-PEG
Paclitaxel
MCF-7, GI-1
Y/N
[203]
PEG-PLGA
Cisplatin and anti-miRNA-21 A2780
Y/N
[64]
PLGA-PVP
Dox
A549
Y/Y
[204]
PEG-PLGA
Gemcitabine
A549
Y/N
[205]
PEG-DGL
Dox
HeLa
Y/Y
[206]
PEG-PAMAM
Camptothecin
HT29, C26
Y/Y
[205]
PEG-PAMAM
5-flfluorouracil
MKN45
Y/Y
[207]
Alkyl-modified PAMAM
Bcl-xLshRNAs
A549
Y/N
[208]
Poly(l-c-glutamyl-glutamine)
Paclitaxel
U87
Y/Y
[209]
DNA nanostructure
Dox
MCF-7/ADR, MCF-7
Y/N
[204]
DNA nanostructure
Epi
C26, MCF-7
Y/Y
[210]
DNA dendrimer nanostructure
Epi
MCF-7, C26
Y/Y
[211]
DNA nanostructure
Dox
PC-3, 4T1
Y/Y
[212]
Cruciform DNA nanostructure
Dox
A549, 4T1
Y/Y
[213]
DNA origami nanorobot
Thrombin
HUVECs
Y/Y
[196]
MSNs
anti-miR-155/5-flfluorouracil SW480
Y/Y
[214]
(continued)